Alnylam Reports 81% Revenue Growth on AMVUTTRA Success, Sets Ambitious 2030 Goals
Event summary
- Alnylam achieved $3B in total net product revenues in 2025, up 81% YoY, driven by AMVUTTRA's U.S. approval for ATTR-CM.
- AMVUTTRA and ONPATTRO combined for $2.5B in 2025 revenues, a 103% YoY increase.
- Company initiated three Phase 3 studies and expanded pipeline with four proprietary CTAs.
- Plans $250M investment in Norton, MA manufacturing facility for siRELIS platform.
- 2026 revenue guidance set at $4.9B–$5.3B, representing 64–77% growth.
The big picture
Alnylam's strong 2025 performance, marked by AMVUTTRA's success and pipeline advancements, positions it as a leader in RNAi therapeutics. The company's ambitious 2030 goals aim to solidify its global TTR leadership while expanding into new disease areas. The planned manufacturing expansion underscores its commitment to scaling production to meet growing demand.
What we're watching
- Pipeline Execution
- Whether Alnylam can sustain momentum with upcoming Phase 2/3 trial results in 2026, including mivelsiran for cerebral amyloid angiopathy and Alzheimer's.
- Manufacturing Scaling
- The pace at which the new siRELIS platform can expand capacity and reduce production costs to support future launches.
- Market Positioning
- How AMVUTTRA's market share will evolve against competitors in the ATTR-CM space following its landmark approval.
Related topics